Nanobiotix S.A. files 6-K

Nanobiotix S.A. reported promising initial efficacy responses in the CONVERGE trial for Stage 3 unresectable Non-Small Cell Lung Cancer (NSCLC) patients, with an 85.7% Objective Response Rate (ORR) and 57.1% Complete Response Rate (CRR) observed in seven patients. The company also announced a protocol amendment for the NANORAY-312 Phase 3 trial in head and neck cancer, which may accelerate the global registration pathway for JNJ-1900 (NBTXR3).